Encephalitis in Loa-Loa Filariasis by L
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Eisai Announces Results and Continued Support Of
No.17-18 April 19, 2017 Eisai Co., Ltd. EISAI ANNOUNCES RESULTS AND CONTINUED SUPPORT OF INITIATIVES FOR ELIMINATION OF LYMPHATIC FILARIASIS 5 YEAR ANNIVERSARY OF LONDON DECLARATION ON NEGLECTED TROPICAL DISEASES Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) has announced the results of its initiatives for the elimination of lymphatic filariasis (LF), and its continued support of this cause in the future. This announcement was made at an event held in Geneva, Switzerland, on April 18, marking the 5th anniversary of the London Declaration on Neglected Tropical Diseases (NTDs), an international public-private partnership. Announced in January 2012, the London Declaration is the largest public-private partnership in the field of global health, and represents a coordinated effort by global pharmaceutical companies, the Bill & Melinda Gates Foundation, the World Health Organization (WHO), the United States, United Kingdom and NTD-endemic country governments, as well as other partners, to eliminate 10 NTDs by the year 2020. Since the signing of the London Declaration, donations of medical treatments by pharmaceutical companies have increased by 70 percent, and these treatments contribute to the prevention and cure of disease in approximately 1 billion people every year. Under the London Declaration, Eisai signed an agreement with WHO to supply 2.2 billion high-quality diethylcarbamazine (DEC) tablets, which were running in short supply worldwide, at Price Zero (free of charge) by the year 2020. These DEC tablets are manufactured at Eisai’s Vizag Plant in India. As of the end of March 2017, 1 billion tablets have been supplied to 27 endemic countries. -
Pathophysiology and Gastrointestinal Impacts of Parasitic Helminths in Human Being
Research and Reviews on Healthcare: Open Access Journal DOI: 10.32474/RRHOAJ.2020.06.000226 ISSN: 2637-6679 Research Article Pathophysiology and Gastrointestinal Impacts of Parasitic Helminths in Human Being Firew Admasu Hailu1*, Geremew Tafesse1 and Tsion Admasu Hailu2 1Dilla University, College of Natural and Computational Sciences, Department of Biology, Dilla, Ethiopia 2Addis Ababa Medical and Business College, Addis Ababa, Ethiopia *Corresponding author: Firew Admasu Hailu, Dilla University, College of Natural and Computational Sciences, Department of Biology, Dilla, Ethiopia Received: November 05, 2020 Published: November 20, 2020 Abstract Introduction: This study mainly focus on the major pathologic manifestations of human gastrointestinal impacts of parasitic worms. Background: Helminthes and protozoan are human parasites that can infect gastrointestinal tract of humans beings and reside in intestinal wall. Protozoans are one celled microscopic, able to multiply in humans, contributes to their survival, permits serious infections, use one of the four main modes of transmission (direct, fecal-oral, vector-borne, and predator-prey) and also helminthes are necked multicellular organisms, referred as intestinal worms even though not all helminthes reside in intestines. However, in their adult form, helminthes cannot multiply in humans and able to survive in mammalian host for many years due to their ability to manipulate immune response. Objectives: The objectives of this study is to assess the main pathophysiology and gastrointestinal impacts of parasitic worms in human being. Methods: Both primary and secondary data were collected using direct observation, books and articles, and also analyzed quantitativelyResults and and conclusion: qualitatively Parasites following are standard organisms scientific living temporarily methods. in or on other organisms called host like human and other animals. -
Co-Infection with Onchocerca Volvulus and Loa Loa Microfilariae in Central Cameroon: Are These Two Species Interacting?
843 Co-infection with Onchocerca volvulus and Loa loa microfilariae in central Cameroon: are these two species interacting? S. D. S. PION1,2*, P. CLARKE3, J. A. N. FILIPE2,J.KAMGNO1,J.GARDON1,4, M.-G. BASA´ N˜ EZ2 and M. BOUSSINESQ1,5 1 Laboratoire mixte IRD (Institut de Recherche pour le De´veloppement) – CPC (Centre Pasteur du Cameroun) d’Epide´miologie et de Sante´ publique, Centre Pasteur du Cameroun, BP 1274, Yaounde´, Cameroun 2 Department of Infectious Disease Epidemiology, St Mary’s campus, Norfolk Place, London W2 1PG, UK 3 Infectious Disease Epidemiology Unit London School of Hygiene and Tropical Medicine Keppel Street, London WC1E 7HT, UK 4 Institut de Recherche pour le De´veloppement, UR 24 Epide´miologie et Pre´vention, CP 9214 Obrajes, La Paz, Bolivia 5 Institut de Recherche pour le De´veloppement, De´partement Socie´te´s et Sante´, 213 rue La Fayette, 75480 Paris Cedex 10, France (Received 16 August 2005; revised 3 October; revised 9 December 2005; accepted 9 December 2005; first published online 10 February 2006) SUMMARY Ivermectin treatment may induce severe adverse reactions in some individuals heavily infected with Loa loa. This hampers the implementation of mass ivermectin treatment against onchocerciasis in areas where Onchocerca volvulus and L. loa are co-endemic. In order to identify factors, including co-infections, which may explain the presence of high L. loa micro- filaraemia in some individuals, we analysed data collected in 19 villages of central Cameroon. Two standardized skin snips and 30 ml of blood were obtained from each of 3190 participants and the microfilarial (mf) loads of both O. -
Performance of Two Serodiagnostic Tests for Loiasis in A
Performance of two serodiagnostic tests for loiasis in a Non-Endemic area Federico Gobbi, Dora Buonfrate, Michel Boussinesq, Cédric Chesnais, Sébastien Pion, Ronaldo Silva, Lucia Moro, Paola Rodari, Francesca Tamarozzi, Marco Biamonte, et al. To cite this version: Federico Gobbi, Dora Buonfrate, Michel Boussinesq, Cédric Chesnais, Sébastien Pion, et al.. Perfor- mance of two serodiagnostic tests for loiasis in a Non-Endemic area. PLoS Neglected Tropical Dis- eases, Public Library of Science, 2020, 14 (5), pp.e0008187. 10.1371/journal.pntd.0008187. inserm- 02911633 HAL Id: inserm-02911633 https://www.hal.inserm.fr/inserm-02911633 Submitted on 4 Aug 2020 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. PLOS NEGLECTED TROPICAL DISEASES RESEARCH ARTICLE Performance of two serodiagnostic tests for loiasis in a Non-Endemic area 1 1 2 2 Federico GobbiID *, Dora Buonfrate , Michel Boussinesq , Cedric B. Chesnais , 2 1 1 1 3 Sebastien D. Pion , Ronaldo Silva , Lucia Moro , Paola RodariID , Francesca Tamarozzi , Marco Biamonte4, Zeno Bisoffi1,5 1 IRCCS Sacro -
For Onchocerciasis on Parasitological Indicators of Loa Loa Infection
pathogens Article Collateral Impact of Community-Directed Treatment with Ivermectin (CDTI) for Onchocerciasis on Parasitological Indicators of Loa loa Infection Hugues C. Nana-Djeunga 1,*, Cédric G. Lenou-Nanga 1, Cyrille Donfo-Azafack 1, Linda Djune-Yemeli 1, Floribert Fossuo-Thotchum 1, André Domche 1, Arsel V. Litchou-Tchuinang 1, Jean Bopda 1, Stève Mbickmen-Tchana 1, Thérèse Nkoa 2, Véronique Penlap 3, Francine Ntoumi 4,5 and Joseph Kamgno 1,6,* 1 Centre for Research on Filariasis and Other Tropical Diseases, P.O. Box 5797, Yaoundé, Cameroon; [email protected] (C.G.L.-N.); [email protected] (C.D.-A.); [email protected] (L.D.-Y.); fl[email protected] (F.F.-T.); [email protected] (A.D.); [email protected] (A.V.L.-T.); bopda@crfilmt.org (J.B.); mbickmen@crfilmt.org (S.M.-T.) 2 Ministry of Public Health, Yaoundé, Cameroon; [email protected] 3 Department of Biochemistry, Faculty of Science, University of Yaoundé 1, P.O. Box 812, Yaoundé, Cameroon; [email protected] 4 Fondation Congolaise pour la Recherche Médicale (FCRM), Brazzaville CG-BZV, Republic of the Congo; [email protected] 5 Faculty of Science and Technology, Marien Ngouabi University, P.O. Box 69, Brazzaville, Republic of the Congo 6 Department of Public Health, Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1, P.O. Box 1364, Yaoundé, Cameroon * Correspondence: nanadjeunga@crfilmt.org (H.C.N.-D.); kamgno@crfilmt.org (J.K.); Tel.: +237-699-076-499 (H.C.N.-D.); +237-677-789-736 (J.K.) Received: 24 October 2020; Accepted: 9 December 2020; Published: 12 December 2020 Abstract: Ivermectin (IVM) is a broad spectrum endectocide whose initial indication was onchocerciasis. -
The Immunology of Filariasis*
Articles in the Update series Les articles de la rubrique give a concise, authoritative, Le point fournissent un and up-to-date survey of the bilan concis et fiable de la present position in the se- situation actuelle dans le a e lected fields, and, over a domaine considere. Des ex- ,,v period of years, will cover / perts couvriront ainsi suc- / many different aspects of cessivement de nombreux the biomedical sciences aspects des sciences bio- e nVlfo l l gZ / / and public health. Most of medicales et de la sante the articles will be writ- publique. La plupart de ces ten, by invitation, by ac- articles auront donc ee knowledged experts on the rediges sur demande par les subject. specialistes les plus autorises. Bulletin of the World Health Organization, 59 (1): 1-8 (1981) The immunology of filariasis* SCIENTIFIC WORKING GROUP ON FILARIASIS1 This report summarizes the available information on the immunology of filariasis, and discusses immunodiagnosis and the immunologicalfactors influencing the host-parasite relationship in lymphaticfilariasis and onchocerciasis. Severalareas that requirefurther research are identifed, particularly concerning the development of new serological techniques, and the fractionation of specific antigens. The problems associated with vaccine development are considered and the importance of finding better animal modelsfor research is stressed. Lymphatic filariasis and onchocerciasis are recognized as important public health problems in many tropical and subtropical areas. However, until recently, little was known about the natural history of filariasis or the immune mechanisms involved. This report summarizes current knowledge on various aspects of the immunology of the disease and outlines areas for future research. -
1 Summary of the Thirteenth Meeting of the ITFDE (II) October 29, 2008
Summary of the Thirteenth Meeting of the ITFDE (II) October 29, 2008 The Thirteenth Meeting of the International Task Force for Disease Eradication (ITFDE) was convened at The Carter Center from 8:30am to 4:00 pm on October 29, 2008. Topics discussed at this meeting were the status of the global campaigns to eliminate lymphatic filariasis (LF) and to eradicate dracunculiasis (Guinea worm disease), an update on efforts to eliminate malaria and LF from the Caribbean island of Hispaniola (Dominican Republic and Haiti), and a report on the First Program Review for Buruli ulcer programs. The Task Force members are Dr. Olusoji Adeyi, The World Bank; Sir George Alleyne, Johns Hopkins University; Dr. Julie Gerberding, Centers for Disease Control and Prevention (CDC); Dr. Donald Hopkins, The Carter Center (Chair); Dr. Adetokunbo Lucas, Harvard University; Professor David Molyneux, Liverpool School of Tropical Medicine (Rtd.); Dr. Mark Rosenberg, Task Force for Child Survival and Development; Dr. Peter Salama, UNICEF; Dr. Lorenzo Savioli, World Health Organization (WHO); Dr. Harrison Spencer, Association of Schools of Public Health; Dr. Dyann Wirth, Harvard School of Public Health, and Dr. Yoichi Yamagata, Japan International Cooperation Agency (JICA). Four of the Task Force members (Hopkins, Adeyi, Lucas, Rosenberg) attended this meeting, and three others were represented by alternates (Dr. Stephen Blount for Gerberding, Dr. Mark Young for Dr. Salama, Dr. Dirk Engels for Savioli). Presenters at this meeting were Dr. Eric Ottesen of the Task Force for Child Survival and Development, Dr. Patrick Lammie of the CDC, Dr. Ernesto Ruiz-Tiben of The Carter Center, Dr. David Joa Espinal of the National Center for Tropical Disease Control (CENCET) in the Dominican Republic, and Dr. -
2. Studies on the Multiplication of Chkunya Virus (CHV), and on Physical and Chemical Structure of Its Virion
71 PAPER IN SCIENTIFIC SESSION GROUP A: Immunology and Viral Diseases 1. Principles and Applications of Fluorescent Antibody Technique in Tropical Medicine Akira Kawamura Department of Immunology, Institute of Medical Science, University of Tokyo, Tokyo, Japan 2. Studies on the Multiplication of Chkunya Virus (CHV), and on Physical and Chemical Structure of its Virion Noboru Higashi,Yasuko Nagatomo, Akira Tamura and Toshio Ametani Virus Institute, Kyoto University, Kyoto, Japan 3. Electronmicroscopic Studies on the Multiplications of Japanese Encephalitis Viurs Noboru Higashi*, Toshiko Ametani*, Yasuko Nagatomo*, Eiichi Fujiwara* and Takashi Tsuruhara** *Virus Institute, Kyoto Uniuersity, Kyoto, Japan and **NIH of Japan , Tokyo, Japan 4. Electromicroscopic Studies on the Multiplication of Dengue Virus Noboru Higashi*, Masao Tokuda*, Toshio Ametani*, Mya-Tu, My My Khin** and Toe Myint** *Virus Institute, Kyoto University, Kyoto, Japan and **Viral Section , Burma Medical Institute, Buruma 72 5. A Plaque Assay of Dengue and Other Arboviruses in Monolayer Cultures of BHK-21 Cells Hideo Aoki Department of Microbiology, School of Medicine Kobe University, Kobe, Japan A cell line of baby hamster kidney (BHK-21, clone 13) was found suitable for titration and multiplication of many kinds of arboviruses, including all types of dengue and related viruses. For instance, dengue (type 1, Hawaiian, Mochizuki ; type 2, New Guinea B ; type 3, H-87 ; type 4, H-241 ; type 5 ? Th-36 ; type 6 ? Th-Sman), JBE Nakayama, JaGar # 01, Gl) and Chikungunya (African) viruses are capable of producing clear plaques in monolayer cultures of the cells under a methyl cellulose overlay medium. By means of this plaque assay system, titration and neutralization of these arboviruses are possible. -
Efficacy and Safety of High-Dose Ivermectin for Reducing Malaria
JMIR RESEARCH PROTOCOLS Smit et al Protocol Efficacy and Safety of High-Dose Ivermectin for Reducing Malaria Transmission (IVERMAL): Protocol for a Double-Blind, Randomized, Placebo-Controlled, Dose-Finding Trial in Western Kenya Menno R Smit1, MD, MPH; Eric Ochomo2, PhD; Ghaith Aljayyoussi1, PhD; Titus Kwambai2,3, MSc, MD; Bernard Abong©o2, MSc; Nabie Bayoh4, PhD; John Gimnig4, PhD; Aaron Samuels4, MHS, MD; Meghna Desai4, MPH, PhD; Penelope A Phillips-Howard1, PhD; Simon Kariuki2, PhD; Duolao Wang1, PhD; Steve Ward1, PhD; Feiko O ter Kuile1, MD, PhD 1Liverpool School of Tropical Medicine (LSTM), Liverpool, United Kingdom 2Centre for Global Health Research, Kenya Medical Research Institute (KEMRI), Kisumu, Kenya 3Kisumu County, Kenya Ministry of Health (MoH), Kisumu, Kenya 4Division of Parasitic Diseases and Malaria, Center for Global Health, U.S. Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States Corresponding Author: Menno R Smit, MD, MPH Liverpool School of Tropical Medicine (LSTM) Pembroke Place Liverpool, L3 5QA United Kingdom Phone: 254 703991513 Fax: 44 1517053329 Email: [email protected] Abstract Background: Innovative approaches are needed to complement existing tools for malaria elimination. Ivermectin is a broad spectrum antiparasitic endectocide clinically used for onchocerciasis and lymphatic filariasis control at single doses of 150 to 200 mcg/kg. It also shortens the lifespan of mosquitoes that feed on individuals recently treated with ivermectin. However, the effect after a 150 to 200 mcg/kg oral dose is short-lived (6 to 11 days). Modeling suggests higher doses, which prolong the mosquitocidal effects, are needed to make a significant contribution to malaria elimination. -
Toxocariasis: Visceral Larva Migrans in Children Toxocaríase: Larva Migrans Visceral Em Crianças E Adolescentes
0021-7557/11/87-02/100 Jornal de Pediatria Copyright © 2011 by Sociedade Brasileira de Pediatria ARTIGO DE REVISÃO Toxocariasis: visceral larva migrans in children Toxocaríase: larva migrans visceral em crianças e adolescentes Elaine A. A. Carvalho1, Regina L. Rocha2 Resumo Abstract Objetivos: Apresentar investigação detalhada de fatores de risco, Objectives: To present a detailed investigation of risk factors, sintomatologia, exames laboratoriais e de imagem que possam contribuir symptoms, and laboratory and imaging tests that may be useful to para o diagnóstico clínico-laboratorial da larva migrans visceral (LMV) em establish the clinical laboratory diagnosis of visceral larva migrans (VLM) crianças e mostrar a importância do diagnóstico e do tratamento para in children, demonstrating the importance of diagnosis and treatment to evitar complicações oculares, hepáticas e em outros órgãos. prevent complications in the eyes, liver, and other organs. Fontes dos dados: Revisão de literatura utilizando os bancos de Sources: Literature review using the MEDLINE and LILACS (1952- dados MEDLINE e LILACS (1952-2009), selecionando os artigos mais 2009) databases, selecting the most recent and representative articles atuais e representativos do tema. on the topic. Síntese dos dados: LMV é uma doença infecciosa de apresentação Summary of the findings: VLM is an infectious disease with non- clínica inespecífica cuja transmissão está relacionada ao contato com cães, specific clinical presentation, whose transmission is related to contact principalmente filhotes, podendo evoluir com complicações sistêmicas with dogs, especially puppies, and which may progress to late systemic tardias em órgãos vitais como o olho e sistema nervoso central. Para complications in vital organs such as the eyes and the central nervous diagnóstico laboratorial, pode ser utilizado IgG (ELISA) anti-Toxocara system. -
Developing Vaccines to Combat Hookworm Infection and Intestinal Schistosomiasis
REVIEWS Developing vaccines to combat hookworm infection and intestinal schistosomiasis Peter J. Hotez*, Jeffrey M. Bethony*‡, David J. Diemert*‡, Mark Pearson§ and Alex Loukas§ Abstract | Hookworm infection and schistosomiasis rank among the most important health problems in developing countries. Both cause anaemia and malnutrition, and schistosomiasis also results in substantial intestinal, liver and genitourinary pathology. In sub-Saharan Africa and Brazil, co-infections with the hookworm, Necator americanus, and the intestinal schistosome, Schistosoma mansoni, are common. The development of vaccines for these infections could substantially reduce the global disability associated with these helminthiases. New genomic, proteomic, immunological and X-ray crystallographic data have led to the discovery of several promising candidate vaccine antigens. Here, we describe recent progress in this field and the rationale for vaccine development. In terms of their global health impact on children and that combat hookworm and schistosomiasis, with an pregnant women, as well as on adults engaged in subsist- emphasis on disease caused by Necator americanus, the ence farming, human hookworm infection (known as major hookworm of humans, and Schistosoma mansoni, ‘hookworm’) and schistosomiasis are two of the most the primary cause of intestinal schistosomiasis. common and important human infections1,2. Together, their disease burdens exceed those of all other neglected Global distribution and pathobiology tropical diseases3–6. They also trap the world’s poorest Hookworms are roundworm parasites that belong to people in poverty because of their deleterious effects the phylum Nematoda. They share phylogenetic simi- on child development and economic productivity7–9. larities with the free-living nematode Caenorhabditis Until recently, the importance of these conditions as elegans and with the parasitic nematodes Nippostrongylus global health and economic problems had been under- brasiliensis and Heligmosomoides polygyrus, which are appreciated. -
Parasites in Liver & Biliary Tree
Parasites in Liver & Biliary tree Luis S. Marsano, MD Professor of Medicine Division of Gastroenterology, Hepatology and Nutrition University of Louisville & Louisville VAMC 2011 Parasites in Liver & Biliary Tree Hepatic Biliary Tree • Protozoa • Protozoa – E. histolytica – Cryptosporidiasis – Malaria – Microsporidiasis – Babesiosis – Isosporidiasis – African Trypanosomiasis – Protothecosis – S. American Trypanosomiasis • Trematodes – Visceral Leishmaniasis – Fascioliasis – Toxoplasmosis – Clonorchiasis • Cestodes – Opistorchiasis – Echynococcosis • Nematodes • Trematodes – Ascariasis – Schistosomiasis • Nematodes – Toxocariasis – Hepatic Capillariasis – Strongyloidiasis – Filariasis Parasites in the Liver Entamoeba histolytica • Organism: E. histolytica is a Protozoa Sarcodina that infects 1‐ 5% of world population and causes 100000 deaths/y. – (E. dispar & E. moshkovskii are morphologically identical but only commensal; PCR or ELISA in stool needed to differentiate). • Distribution: worldwide; more in tropics and areas with poor sanitation. • Location: colonic lumen; may invade crypts and capillaries. More in cecum, ascending, and sigmoid. • Forms: trophozoites (20 mcm) or cysts (10‐20 mcm). Erytrophagocytosis is diagnostic for E. histolytica trophozoite. • Virulence: may increase with immunosuppressant drugs, malnutrition, burns, pregnancy and puerperium. Entamoeba histolytica • Clinical forms: – I) asymptomatic; – II) symptomatic: • A. Intestinal: – a) Dysenteric, – b) Nondysenteric colitis. • B. Extraintestinal: – a) Hepatic: i) acute